Myomo Adds Healthcare Tech Veteran to Board Amid Growth Push
Event summary
- Myomo appoints William J. Febbo to its board of directors effective April 14, 2026.
- Febbo brings over 30 years of experience in healthcare, financial services, and technology-driven businesses.
- He previously led OptimizeRx Corporation, growing revenue from $5M to $92M with a five-year CAGR of 41%.
- Myomo now has six directors on its board.
The big picture
Myomo's appointment of William J. Febbo reflects a strategic move to leverage his extensive experience in scaling healthcare technology companies. His background in transforming OptimizeRx Corporation into an AI-driven omnichannel platform suggests a focus on digital health innovation and capital markets expansion. This aligns with Myomo's goal of becoming a market leader in advanced upper extremity orthotics, particularly as the healthcare industry increasingly adopts robotics.
What we're watching
- Scaling Strategy
- How Febbo's expertise in direct-to-patient healthcare solutions will impact Myomo's growth trajectory.
- Capital Markets Awareness
- Whether Febbo's credibility within capital markets can increase overall awareness of Myomo as a solid investment thesis.
- Product Development
- The pace at which Myomo can innovate and commercialize its product line under Febbo's guidance.
Related topics